GTx, Inc. (NASDAQ:GTXI) has received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.
Brokers have set a one year consensus price target of $16.50 for the company and are predicting that the company will post ($0.39) earnings per share for the current quarter, according to Zacks. Zacks has also given GTX an industry rank of 189 out of 265 based on the ratings given to its competitors.
Several analysts recently weighed in on the stock. Stifel Nicolaus assumed coverage on shares of GTX in a research note on Thursday, November 9th. They issued a “buy” rating on the stock. ValuEngine raised shares of GTX from a “sell” rating to a “hold” rating in a research note on Wednesday. Zacks Investment Research raised shares of GTX from a “sell” rating to a “hold” rating in a research note on Wednesday, January 17th. Robert W. Baird assumed coverage on shares of GTX in a research note on Tuesday, November 21st. They issued an “outperform” rating and a $17.00 price objective on the stock. Finally, BidaskClub raised shares of GTX from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 26th.
GTX (NASDAQ:GTXI) last posted its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.25). research analysts forecast that GTX will post -1.61 earnings per share for the current fiscal year.
In other GTX news, VP Henry Patton Doggrell sold 4,965 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $11.33, for a total transaction of $56,253.45. Following the sale, the vice president now owns 54,804 shares of the company’s stock, valued at $620,929.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jason T. Shackelford sold 3,090 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $11.33, for a total transaction of $35,009.70. Following the sale, the insider now directly owns 31,111 shares in the company, valued at approximately $352,487.63. The disclosure for this sale can be found here. In the last three months, insiders sold 15,364 shares of company stock worth $174,074. 41.20% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of GTXI. Bank of New York Mellon Corp bought a new stake in GTX during the second quarter valued at $124,000. Abingworth LLP bought a new stake in GTX during the third quarter valued at $2,781,000. Finally, Caxton Corp bought a new stake in GTX during the third quarter valued at $531,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.
GTX Company Profile
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.